Concordia International Corp. together with its subsidiaries announced it has entered into a three-year, co-promotion agreement with RedHill Biopharma Ltd. through which the companies expect to expand sales of Donnatal®, Concordia's product used in the treatment of irritable bowel syndrome. Under the terms of the agreement, RedHill intends to increase the promotion of Donnatal® among U.S. doctors who treat irritable bowel syndrome, with marketing efforts anticipated to begin during the current quarter.

Over the three-year period, RedHill intends to promote the product in up to 30 sales territories. RedHill will incur the sales and marketing costs associated with promotional activities, while Concordia will provide materials and samples. Concordia will keep all revenue up to a predetermined level of sales and only after reaching that predetermined level will revenue be shared between the Company and RedHill.

Concordia also plans to continue to sell Donnatal® in U.S. sales territories outside the scope of the RedHill agreement.